Verhoef P, Hennekens C H, Malinow M R, Kok F J, Willett W C, Stampfer M J
Department of Epidemiology and Public Health, Agricultural University, Wageningen, Netherlands.
Stroke. 1994 Oct;25(10):1924-30. doi: 10.1161/01.str.25.10.1924.
Several studies have reported elevated circulating homocyst(e)ine levels in subjects with cerebral atherosclerosis. We assessed prospectively whether high plasma levels of homocyst(e)ine affect risk of ischemic stroke and evaluated whether high blood pressure modifies any such effect.
The study sample was drawn from the Physicians' Health Study, a randomized, double-blind, placebo-controlled trial of aspirin and beta-carotene in 22,071 US male physicians. A total of 14,916 subjects 40 to 84 years old with no prior history of stroke, transient ischemic attack, or myocardial infarction provided blood samples at baseline and were followed for 5 years, with 99.7% morbidity and 100% mortality follow-up. Using a nested case-control design, we assayed homocyst(e)ine in samples from 109 subjects who subsequently developed ischemic stroke and 427 control subjects.
The mean plasma concentration of homocyst(e)ine was slightly higher in subjects with stroke (11.1 +/- 4.0 [+/- SD] nmol/mL) than in control subjects (10.6 +/- 3.4 nmol/mL), but the difference was not statistically significant (P = .12). The crude odds ratio of ischemic stroke for subjects in the upper 20% (> 12.7 nmol/mL) compared with those in the bottom 80% of homocyst(e)ine levels was 1.4 (95% confidence interval, 0.8 to 2.2). The odds ratio was 1.2 (95% confidence interval, 0.7 to 2.0) after controlling for several risk factors and other potential confounders. In subgroup analyses, elevated homocyst(e)ine levels appeared to be more strongly predictive of ischemic stroke in normotensive subjects and in men 60 years or younger. Although not statistically significant, in these subgroups increases in risks of 100% and 70%, respectively, were observed for men in the upper 20% of homocyst(e)ine values.
In this study, the data were compatible with a small but nonsignificant association between elevated plasma homocyst(e)ine and risk of ischemic stroke. However, since the sample size is small and the confidence intervals are wide, either no association or a moderate increase in risk cannot be excluded, particularly in subgroups otherwise at low risk, eg, younger men and those with normal blood pressure.
多项研究报告称,脑动脉粥样硬化患者的循环同型半胱氨酸水平升高。我们前瞻性地评估了高血浆同型半胱氨酸水平是否会影响缺血性中风风险,并评估了高血压是否会改变这种影响。
研究样本取自医师健康研究,这是一项针对22071名美国男性医师进行的阿司匹林和β-胡萝卜素随机、双盲、安慰剂对照试验。共有14916名年龄在40至84岁之间、无中风、短暂性脑缺血发作或心肌梗死病史的受试者在基线时提供了血样,并随访5年,发病率随访率为99.7%,死亡率随访率为100%。采用巢式病例对照设计,我们检测了109名随后发生缺血性中风的受试者和427名对照受试者样本中的同型半胱氨酸。
中风患者的血浆同型半胱氨酸平均浓度(11.1±4.0[±标准差]nmol/mL)略高于对照受试者(10.6±3.4 nmol/mL),但差异无统计学意义(P = 0.12)。同型半胱氨酸水平处于前20%(>12.7 nmol/mL)的受试者与处于后80%的受试者相比,缺血性中风的粗比值比为1.4(95%置信区间,0.8至2.2)。在控制了多个风险因素和其他潜在混杂因素后,比值比为1.2(95%置信区间,0.7至2.0)。在亚组分析中,同型半胱氨酸水平升高似乎在血压正常的受试者以及60岁及以下男性中对缺血性中风的预测性更强。虽然无统计学意义,但在这些亚组中,同型半胱氨酸值处于前20%的男性的风险分别增加了100%和70%。
在本研究中,数据与血浆同型半胱氨酸升高与缺血性中风风险之间存在小但无统计学意义的关联相符。然而,由于样本量小且置信区间宽,不能排除无关联或风险适度增加的情况,特别是在其他低风险亚组中,如年轻男性和血压正常者。